GSTM1 and anemia (phenotype): Guideline-directed therapy of anemia was associated with a significantly faster and, more importantly, more sustained increase in Hb levels at both the 28-day and 2-month time points (GLAD-T 0: 9.65 g/dL and 9.96 g/dL, respectively, vs. GLAD-T 2 10.15 g/dL and 10.44 g/dL, respectively); see also Fig. 2a.